A Retrospective Study of Rabbit Anti-T Lymphocyte Globulin (rATLG) as a Second-Line Therapy in Transplant-Ineligible Severe Aplastic Anemia Patients
Although modest in efficacy, rATLG offers a clinically meaningful salvage option in transplant-ineligible SAA patients, particularly in low-resource settings where curative transplantation is often inaccessible. Our findings underscore the role of rATLG as a bridge therapy, while highlighting the urgent need for wider access to definitive curative options in developing countries.
Authors
- Alpika Shukla (ORCID: https://orcid.org/0000-0002-2687-0587)
- P. Raghuveer
- Akshay Middinti
- Raj Kumar Maurya (ORCID: https://orcid.org/0000-0002-4294-278X)
- Anjan K. Saha (ORCID: https://orcid.org/0000-0001-6721-1599)
- Gaurav Datta (ORCID: https://orcid.org/0009-0009-6842-8613)
- Swasti Sinha (ORCID: https://orcid.org/0000-0002-2413-8894)
- Shailendra Verma (ORCID: https://orcid.org/0000-0002-6911-9064)
Institutions
- King George's Medical University (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-11-28
- DOI
- https://doi.org/10.7759/cureus.98014
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00